Palliative chemotherapy: oxymoron or misunderstanding?
dc.contributor.author | Roeland, EJ | |
dc.contributor.author | LeBlanc, TW | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2017-02-24T17:47:06Z | |
dc.date.accessioned | 2017-03-14T16:59:33Z | |
dc.date.accessioned | 2017-03-16T13:46:48Z | |
dc.date.available | 2017-03-16T13:46:48Z | |
dc.date.issued | 2016-03-21 | |
dc.description.abstract | Oncologists routinely prescribe chemotherapy for patients with advanced cancer. This practice is sometimes misunderstood by palliative care clinicians, yet data clearly show that chemotherapy can be a powerful palliative intervention when applied appropriately. Clarity regarding the term "palliative chemotherapy" is needed: it is chemotherapy given in the non-curative setting to optimize symptom control, improve quality of life, and sometimes to improve survival. Unfortunately, oncologists lack adequate tools to predict which patients will benefit. In a study recently published in BMC Palliative Care, Creutzfeldt et al. presented an innovative approach to advancing the science in this area: using patient reported outcomes to predict responses to palliative chemotherapy. With further research, investigators may be able to develop predictive models for use at the bedside to inform clinical decision-making about the risks and benefits of treatment. In the meantime, oncologists and palliative care clinicians must work together to reduce the use of "end-of-life chemotherapy"-chemotherapy given close to death, which does not improve longevity or symptom control-while optimizing the use of chemotherapy that has true palliative benefits for patients. | |
dc.identifier | ||
dc.identifier | 10.1186/s12904-016-0109-4 | |
dc.identifier.eissn | 1472-684X | |
dc.identifier.uri | ||
dc.language | eng | |
dc.publisher | Springer Science and Business Media LLC | |
dc.relation.ispartof | BMC Palliat Care | |
dc.relation.isversionof | 10.1186/s12904-016-0109-4 | |
dc.relation.replaces | ||
dc.relation.replaces | 10161/13675 | |
dc.relation.replaces | ||
dc.relation.replaces | 10161/13824 | |
dc.subject | Humans | |
dc.subject | Neoplasms | |
dc.subject | Palliative Care | |
dc.subject | Quality of Life | |
dc.title | Palliative chemotherapy: oxymoron or misunderstanding? | |
dc.type | Journal article | |
duke.contributor.orcid | LeBlanc, TW|0000-0002-0546-7895 | |
pubs.author-url | ||
pubs.begin-page | 33 | |
pubs.organisational-group | Clinical Science Departments | |
pubs.organisational-group | Duke | |
pubs.organisational-group | Duke Cancer Institute | |
pubs.organisational-group | Institutes and Centers | |
pubs.organisational-group | Medicine | |
pubs.organisational-group | Medicine, Hematological Malignancies | |
pubs.organisational-group | School of Medicine | |
pubs.publication-status | Published online | |
pubs.volume | 15 |
Files
Original bundle
- Name:
- Palliative+chemotherapy-+oxymoron+or+misunderstanding.pdf
- Size:
- 396.69 KB
- Format:
- Adobe Portable Document Format
- Description:
- Published version